Joshua Lev Sells 3,000 Shares of electroCore (NASDAQ:ECOR) Stock

electroCore, Inc. (NASDAQ:ECOR) CFO Joshua Lev sold 3,000 shares of the firm’s stock in a transaction dated Tuesday, August 25th. The stock was sold at an average price of $9.36, for a total value of $28,080.00. Following the transaction, the chief financial officer owned 84,889 shares of the company’s stock, valued at $794,561.04. This trade represents a 3.41% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

electroCore Price Performance

electroCore stock opened at $10.35 on Thursday. The stock’s 50 day moving average is $7.79 and its 200 day moving average is $7.27. electroCore, Inc. has a one year low of $4.41 and a one year high of $10.95. The firm has a market cap of $93.32 million, a P/E ratio of -6.23 and a beta of 0.92.

electroCore (NASDAQ:ECOR) last released its earnings results on Thursday, August 6th. The company reported ($0.33) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.42) by $0.09. electroCore had a negative net margin of 39.96% and a negative return on equity of 1,956.38%. The business had revenue of $9.45 million during the quarter, compared to the consensus estimate of $9.49 million. Equities analysts anticipate that electroCore, Inc. will post -1.4 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Two Sigma Investments LP increased its stake in electroCore by 20.8% in the third quarter. Two Sigma Investments LP now owns 24,603 shares of the company’s stock valued at $122,000 after purchasing an additional 4,231 shares in the last quarter. Cubist Systematic Strategies LLC bought a new position in shares of electroCore during the 1st quarter worth about $153,000. WealthShield Partners LLC acquired a new stake in shares of electroCore in the 1st quarter valued at about $157,000. Jane Street Group LLC grew its stake in shares of electroCore by 114.4% in the 1st quarter. Jane Street Group LLC now owns 36,726 shares of the company’s stock valued at $246,000 after buying an additional 19,599 shares during the period. Finally, DRW Securities LLC bought a new stake in electroCore in the 4th quarter valued at about $264,000. 26.74% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reissued a “sell (d-)” rating on shares of electroCore in a research report on Wednesday, June 24th. One research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $18.00.

Key Stories Impacting electroCore

Here are the key news stories impacting electroCore this week:

• Positive Sentiment: electroCore’s Truvaga® device was named the Best Luxury Biohacking & Longevity Brand in the USA by Luxury Lifestyle Awards. The recognition may improve consumer awareness and support the company’s expansion into the wellness market beyond its prescription-focused nVNS products. Truvaga Named Best Luxury Biohacking & Longevity Brand
• Neutral Sentiment: Reported short interest was zero shares as of August 25, indicating that short sellers are not a significant factor behind current trading activity. Institutional investors own approximately 26.74% of ECOR, with some funds recently adding to their positions.
• Negative Sentiment: CFO Joshua Lev disclosed a series of stock sales totaling 20,000 shares: 12,000 shares at an average $10.22, 5,000 at $9.88 and 3,000 at $9.36. The transactions reduced his direct ownership to 84,889 shares and occurred near the stock’s recent highs, potentially weighing on investor sentiment. electroCore CFO Insider Sales
• Negative Sentiment: electroCore remains unprofitable. In its latest quarter, the company reported a loss of $0.33 per share—better than the expected $0.42 loss—while revenue of $9.45 million was slightly below the $9.49 million consensus estimate. Analysts expect a full-year loss of approximately $1.40 per share, and the overall analyst rating remains “Hold,” alongside a separate “Sell” rating.

About electroCore

electroCore, Inc is a commercial-stage bioelectronic medicine company headquartered in Rockaway, New Jersey. The company specializes in the development and commercialization of non-invasive vagus nerve stimulation (nVNS) therapies designed to address a variety of neurological and inflammatory conditions. Established in 2006, electroCore has focused its efforts on translating neuromodulation science into a compact, patient-administered treatment device.

The company’s lead product, gammaCore®, is a handheld, battery-powered device that delivers nVNS through the skin to the cervical branch of the vagus nerve.